Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 06, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling

Court Denies JDS1’s Motion for Expedited Proceedings Board Reiterates Commitment to Distributing Cash to Stockholders Once Potential Liability and Expenses Associated with Stockholder Litigation and...
June 29, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders

Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set...
May 23, 2022 08:30 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Sells Complement Portfolio for $60 Million

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex...
May 09, 2022 08:30 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31,...
March 31, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended...
March 15, 2022 17:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for...
February 17, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to...
January 25, 2022 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric...
November 22, 2021 08:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside...
November 12, 2021 07:00 ET | Source: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Change in Corporate Strategy

Company to discontinue MarzAA development; focus on developing its complement portfolio Management to host a call today at 8:30 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) --...